Table 1 Univariate cox proportional hazards regression models of progression free survival from chemotherapy start
From: The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma
Variable | Progressed | Total | HR | 95% CI | P |
|---|---|---|---|---|---|
PFS (29 of 40 progressed) | |||||
Treatment arm | |||||
Sorafenib | 19 | 22 | 2.05 | 0.95, 4.45 | 0.0683 |
Sorafenib + interferon | 10 | 18 | 1.00 | ||
ECOG performance status | |||||
1 | 10 | 13 | 4.95 | 2.07, 11.84 | 0.0003 |
0 | 19 | 27 | 1.00 | ||
Anemia | |||||
Yes | 12 | 15 | 2.37 | 1.09, 5.17 | 0.0299 |
No | 17 | 25 | 1.00 | ||
FGFR1 | |||||
(level 1) | 3 | 8 | 1.00 | ||
(level 2) | 15 | 19 | 3.54 | 1.02, 12.29 | 0.0463 |
(level 3 or 4) | 11 | 13 | 4.56 | 1.25, 16.66 | 0.0218 |
FRS2α | |||||
(level 1) | 3 | 7 | 1.00 | ||
(level 2) | 17 | 21 | 2.07 | 0.60, 7.18 | 0.2498 |
(level 3 or 4) | 9 | 12 | 2.87 | 0.77, 10.66 | 0.1146 |